{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:52:06Z","timestamp":1790434326166,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2007\/54709-0"],"award-info":[{"award-number":["2007\/54709-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Expression of matrix metalloproteases 2, 9 and 14 (MMP-2, MMP-9, MMP-14), tissue inhibitors of metalloprotease 1 and 2 (TIMP-1, TIMP-2) and vascular endothelial growth factor A (VEGF-A) is involved in tumor invasion and metastasis via extracellular matrix degradation and angiogenesis. This study aimed to assess whether the expression of MMP-2, MMP-9, MMP-14, TIMP-1, and TIMP-2 in tumors and in the adjacent stroma is associated with cervical cancer prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study analyzed a retrospective cohort of 64 patients. Protein expression was previously obtained by immunohistochemistry from biopsies containing both tumor and stroma. The expression and percentage of stained cells were categorized as high or low according to the cutoff points by using ROC curves. The follow-up data was collected from diagnosis to the last clinical visit. Clinical status categorized as alive without disease, alive with disease, death due to other causes, and death from the disease. The relative risk of death from the disease was evaluated according to the proteins expression using a cause-specific Cox regression model with a 95% confidence interval (95%CI). For the significant associations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), survival curves of patients with low and high expression were plotted for the competing risk survival curve analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High expression levels of stromal MMP-2 (RR; 95%CI: 3.91; 1.17\u201313.02) and stromal TIMP-2 (RR, 95%CI: 8.67; 1.15\u201365.27) were associated with a greater relative risk of death from the disease and with lower survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) than lower expression levels. Low expression levels of stromal MMP-9 (RR, 95%CI: 0.19; 0.05\u20130.65) and tumoral MMP-9 (HR, 95%CI: 0.19; 0.04\u20130.90) were protective factors against death from the disease and were associated with poorer survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High expression levels of MMP-2 and TIMP-2 in the stroma were significantly associated with poor survival in cervical cancer patients. High expression of MMP-9 was associated with a favorable cervical cancer prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07150-3","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T08:02:48Z","timestamp":1594800168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Jordana Maria","family":"Azevedo Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Helena","family":"Rabelo-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"do Amaral Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-0971","authenticated-orcid":false,"given":"Luiz Carlos","family":"Zeferino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"issue":"1","key":"7150_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12\u20139.","journal-title":"J Pathol"},{"issue":"3","key":"7150_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/91.3.252","volume":"91","author":"P Holowaty","year":"1999","unstructured":"Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91(3):252\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"7150_CR3","first-page":"890","volume":"97","author":"O Reich","year":"2001","unstructured":"Reich O, Pickel H, Tamussino K, Winter R. Microinvasive carcinoma of the cervix: site of first focus of invasion. Obstet Gynecol. 2001;97(6):890\u20132.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"7150_CR4","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ajog.2003.12.017","volume":"190","author":"MAM Gaiotto","year":"2004","unstructured":"Gaiotto MAM, Focchi J, Ribalta JL, St\u00e1vale JN, Baracat EC, Lima GR, et al. Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. Am J Obstet Gynecol. 2004;190(5):1278\u201382.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"7150_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.32607\/20758251-2015-7-2-17-28","volume":"7","author":"N Krakhmal","year":"2015","unstructured":"Krakhmal N, Zavyalova M, Denisov E, Vtorushin S, Perelmuter V. Cancer invasion: patterns and mechanisms. Acta Nat. 2015;7(2):17\u201328.","journal-title":"Acta Nat"},{"key":"7150_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","volume":"97","author":"AD Theocharis","year":"2016","unstructured":"Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4\u201327.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"7150_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7150_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","volume":"25","author":"EI Deryugina","year":"2006","unstructured":"Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9\u201334.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"7150_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52\u201367.","journal-title":"Cell."},{"issue":"2","key":"7150_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00432-002-0411-9","volume":"129","author":"SA Nair","year":"2003","unstructured":"Nair SA, Karunagaran D, Nair M, Sudhakaran P. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol. 2003;129(2):123\u201331.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7150_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.apha.2017.08.002","volume-title":"Vascular pharmacology: cytoskeleton and extracellular matrix","author":"X Wang","year":"2018","unstructured":"Wang X, Khalil RA. Matrix Metalloproteinases, vascular remodeling, and vascular disease. In: Khalil RA, editor. Vascular pharmacology: cytoskeleton and extracellular matrix. 81st ed. London: Academic Press; 2018. p. 241\u2013330.","edition":"81"},{"issue":"2B","key":"7150_CR12","first-page":"1543","volume":"26","author":"M Branca","year":"2006","unstructured":"Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, et al. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Res. 2006;26(2B):1543\u20136.","journal-title":"Anticancer Res"},{"issue":"3","key":"7150_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1006\/gyno.1998.5285","volume":"72","author":"B Davidson","year":"1999","unstructured":"Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Weis B, et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - Clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 1999;72(3):380\u20136.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"7150_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10974-015-9414-4","volume":"36","author":"C Snyman","year":"2015","unstructured":"Snyman C, Niesler C. MMP-14 in skeletal muscle repair. J Muscle Res Cell Motil. 2015;36(3):215\u201325.","journal-title":"J Muscle Res Cell Motil"},{"issue":"37","key":"7150_CR15","doi-asserted-by":"publisher","first-page":"59441","DOI":"10.18632\/oncotarget.11118","volume":"7","author":"LS Tarpgaard","year":"2016","unstructured":"Tarpgaard LS, \u00d8rum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, et al. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget. 2016;7(37):59441\u201357.","journal-title":"Oncotarget."},{"issue":"5","key":"7150_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.prp.2015.11.014","volume":"212","author":"HJ An","year":"2016","unstructured":"An HJ, Lee YJ, Hong SA, Kim JO, Lee KY, Kim YK, et al. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. Pathol Res Pract. 2016;212(5):357\u201364.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"7150_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(03)00551-8","volume":"114","author":"DW Seo","year":"2003","unstructured":"Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003;114(2):171\u201380.","journal-title":"Cell."},{"issue":"2","key":"7150_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1582-4934.2005.tb00355.x","volume":"9","author":"JE Rundhaug","year":"2005","unstructured":"Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2):267\u201385.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"7150_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ III, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"7150_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","volume":"17","author":"WJ Koh","year":"2019","unstructured":"Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical Cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(1):64\u201384.","journal-title":"J Natl Compr Cancer Netw"},{"key":"7150_CR21","doi-asserted-by":"crossref","unstructured":"Klopp AH, Eifel PJ. Biological predictors of cervical cancer response to radiation therapy. In: Semin Radiat Oncol. vol. 22. Elsevier; 2012. p. 143\u2013150.","DOI":"10.1016\/j.semradonc.2011.12.009"},{"key":"7150_CR22","unstructured":"World Medical Association. WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects. 2013. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 22 Aug 2017."},{"issue":"S2","key":"7150_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijgo.2015.06.004","volume":"131","author":"A Bermudez","year":"2015","unstructured":"Bermudez A, Bhatla N, Leung E. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2015;131(S2):88\u201395.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"7150_CR24","first-page":"S100","volume":"119","author":"E Wiebe","year":"2014","unstructured":"Wiebe E, Denny L, Thomas G. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2014;119(2):S100\u20139.","journal-title":"Int J Gynaecol Obstet"},{"key":"7150_CR25","first-page":"19","volume":"S3","author":"MCA Westin","year":"2015","unstructured":"Westin MCA, Rabelo-Santos SH, Angelo Andrade LAL, Derchain S, Pinto GA, Morais S, et al. Expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP- 2 in intraepithelial and invasive cervical Neoplasia. J Cytol Histol. 2015;S3:19.","journal-title":"J Cytol Histol."},{"key":"7150_CR26","first-page":"22","volume":"S3","author":"MCA Westin","year":"2015","unstructured":"Westin MCA, Rabelo-Santos SH, Angelo Andrade LAL, Derchain S, Pinto GA, Morais S, et al. Expression of VEGF-A in intraepithelial and invasive cervical Neoplasia. J Cytol Histol. 2015;S3:22.","journal-title":"J Cytol Histol"},{"issue":"3421","key":"7150_CR27","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133(3421):571\u20133.","journal-title":"Lancet"},{"issue":"4","key":"7150_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10238-006-0117-4","volume":"6","author":"D Ribatti","year":"2006","unstructured":"Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the \u2018seed and soil\u2019 theory of metastatic dissemination. Clin Exp Med. 2006;6(4):145\u20139.","journal-title":"Clin Exp Med"},{"issue":"1","key":"7150_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10555-006-7887-8","volume":"25","author":"S Jodele","year":"2006","unstructured":"Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006;25(1):35\u201343.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"7150_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.suronc.2011.09.001","volume":"21","author":"CE Weber","year":"2012","unstructured":"Weber CE, Kuo PC. The tumor microenvironment. Surg Oncol. 2012;21(3):172\u20137.","journal-title":"Surg Oncol"},{"issue":"4","key":"7150_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/path.1398","volume":"200","author":"O De Wever","year":"2003","unstructured":"De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200(4):429\u201347.","journal-title":"J Pathol"},{"issue":"4","key":"7150_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00280-008-0881-9","volume":"63","author":"F Mbeunkui","year":"2009","unstructured":"Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63(4):571\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6835","key":"7150_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/35077241","volume":"411","author":"LA Liotta","year":"2001","unstructured":"Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411(6835):375\u20139.","journal-title":"Nature."},{"issue":"5","key":"7150_CR34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7150_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0959-437X(00)00156-8","volume":"11","author":"T Tlsty","year":"2001","unstructured":"Tlsty T, Hein P. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev. 2001;11(1):54\u20139.","journal-title":"Curr Opin Genet Dev"},{"issue":"1","key":"7150_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ygyno.2003.09.012","volume":"92","author":"T Sato","year":"2004","unstructured":"Sato T, Sakaia T, Noguchi Y, Hirakawa MTS, Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 2004;92(1):47\u201356.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"7150_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00428-018-2408-z","volume":"473","author":"G van Pelt","year":"2018","unstructured":"van Pelt G, Kj\u00e6r-Frifeldt S, van Krieken J, Al Dieri R, Morreau H, Tollenaar R, et al. Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. Virchows Arch. 2018;473(4):405\u201312.","journal-title":"Virchows Arch"},{"issue":"10","key":"7150_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/apm.12889","volume":"126","author":"B Ahn","year":"2018","unstructured":"Ahn B, Chae YS, Kim CH, Lee Y, Lee JH, Kim JY. Tumor microenvironmental factors have prognostic significances in advanced gastric cancer. APMIS. 2018;126(10):814\u201321.","journal-title":"APMIS."},{"issue":"4","key":"7150_CR39","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41416-018-0202-y","volume":"119","author":"N Kemi","year":"2018","unstructured":"Kemi N, Eskuri M, Herva A, Lepp\u00e4nen J, Huhta H, Helminen O, et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br J Cancer. 2018;119(4):435\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"7150_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-018-4987-4","volume":"173","author":"CJH Kramer","year":"2018","unstructured":"Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Breast Cancer Res Treat. 2018;173(1):55\u201364.","journal-title":"Breast Cancer Res Treat"},{"key":"7150_CR41","doi-asserted-by":"crossref","unstructured":"Wang HL, Zhou PY, Zhang Y, Liu P. Relationships between abnormal MMP2 expression and prognosis in gastric cancer: a meta-analysis of cohort studies. Cancer Biother Radiopharm. 2014;29(4):166\u201372. 42.","DOI":"10.1089\/cbr.2014.1608"},{"key":"7150_CR42","doi-asserted-by":"crossref","unstructured":"Lu X, Duan L, Xie H, Lu X, Lu D, Lu D, et al. Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction. Onco Targets Ther. 2016;9.","DOI":"10.2147\/OTT.S99580"},{"key":"7150_CR43","doi-asserted-by":"crossref","unstructured":"Liu C, Li Y, Hu S, Chen Y, Gao L, Liu D, et al. Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and meta-analysis. Medicine. 2018;97(29).","DOI":"10.1097\/MD.0000000000010994"},{"issue":"7","key":"7150_CR44","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/sj.bjc.6601238","volume":"89","author":"A Talvensaari-Mattila","year":"2003","unstructured":"Talvensaari-Mattila A, P\u00e4\u00e4kk\u00f6 P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89(7):1270\u20135.","journal-title":"Br J Cancer"},{"issue":"4","key":"7150_CR45","first-page":"341","volume":"29","author":"R Fernandes","year":"2008","unstructured":"Fernandes R, Morais S, Pinto G, Chagas C, Maria-Engler S, Zeferino LC. Stromal cells play a role in cervical cancer progression mediated by MMP\u20132 protein. Eur J Gynaec Oncol. 2008;29(4):341\u20134.","journal-title":"Eur J Gynaec Oncol"},{"issue":"4","key":"7150_CR46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1615\/JEnvironPatholToxicolOncol.v25.i4.50","volume":"25","author":"A Mitra","year":"2006","unstructured":"Mitra A, Chakrabarti J, Banerji A, Chatterjee A. Cell membrane-associated MT1-MMP dependent activation of MMP-2 in SiHa (human cervical Cancer) cells. J Environ Pathol Toxicol Oncol. 2006;25(4):655\u201366.","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"34","key":"7150_CR47","doi-asserted-by":"publisher","first-page":"13310","DOI":"10.1074\/jbc.RA118.004406","volume":"293","author":"G Yosef","year":"2018","unstructured":"Yosef G, Arkadash V, Papo N. Targeting the MMP-14\/MMP-2\/integrin \u03b1v\u03b23 axis with multispecific N-TIMP2-based antagonists for cancer therapy. J Biol Chem. 2018;293(34):13310\u201326.","journal-title":"J Biol Chem"},{"key":"7150_CR48","doi-asserted-by":"crossref","unstructured":"Lubowicka E, Zbucka-Kretowska M, Sidorkiewicz I, Zajkowska M, Gacuta E, Puchnarewicz A, et al. Diagnostic power of cytokine M-CSF, metalloproteinase 2 (MMP-2) and tissue Inhibitor-2 (TIMP-2) in cervical Cancer patients based on ROC analysis. Pathol Oncol Res. 2019;p. 1\u201310.","DOI":"10.1007\/s12253-019-00626-z"},{"issue":"24","key":"7150_CR49","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.1158\/1078-0432.CCR-04-0424","volume":"10","author":"S Curran","year":"2004","unstructured":"Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase\/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10(24):8229\u201334.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7150_CR50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1369\/0022155412446978","volume":"60","author":"A Hal\u00f3n","year":"2012","unstructured":"Hal\u00f3n A, Nowak-Markwitz E, Donizy P, Matkowski R, Maciejczyk A, Gansukh T, et al. Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. J Histochem Cytochem. 2012;60(7):491\u2013501.","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"7150_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1155\/2013\/416870","volume":"35","author":"M Honkavuori-Toivola","year":"2013","unstructured":"Honkavuori-Toivola M, Santala M, Soini Y, Turpeenniemi-Hujanen T, Talvensaari-Mattila A. Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma. Dis Markers. 2013;35(4):261\u20136.","journal-title":"Dis Markers"},{"key":"7150_CR52","doi-asserted-by":"crossref","unstructured":"Zhu L, Yu H, Liu SY, Xiao XS, Dong WH, Chen YN, et al. Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2015;10(4).","DOI":"10.1371\/journal.pone.0124230"},{"issue":"10","key":"7150_CR53","first-page":"1311","volume":"101","author":"K Kanjanapradit","year":"2018","unstructured":"Kanjanapradit K, Thongsuksai P, Phukaoloun M, Geater SL. Prognostic significance of tissue inhibitor of matrix metalloproteinase-2 [TIMP-2] expression in non-small cell carcinoma of lung. J Med Assoc Thail. 2018;101(10):1311\u20137.","journal-title":"J Med Assoc Thail"},{"issue":"1","key":"7150_CR54","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41598-018-19268-3","volume":"8","author":"W Wang","year":"2018","unstructured":"Wang W, Zhang Y, Liu M, Wang Y, Yang T, Li D, et al. TIMP2 is a poor prognostic factor and predicts metastatic biological behavior in gastric Cancer. Sci Rep. 2018;8(1):962\u20139.","journal-title":"Sci Rep"},{"issue":"3","key":"7150_CR55","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/bcr1503","volume":"8","author":"B T\u00eatu","year":"2006","unstructured":"T\u00eatu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res. 2006;8(3):R28.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"7150_CR56","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12013-014-9974-8","volume":"70","author":"H Wang","year":"2014","unstructured":"Wang H, Zhang X, Huang L, Li J, Qu S, Pan F. Matrix metalloproteinase\u201314 expression and its prognostic value in cervical carcinoma. Cell Biochem Biophys. 2014;70(2):729\u201334.","journal-title":"Cell Biochem Biophys"},{"issue":"2","key":"7150_CR57","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/(SICI)1097-0215(19990719)82:2<208::AID-IJC10>3.0.CO;2-9","volume":"82","author":"M Chenard","year":"1999","unstructured":"Chenard M, Lutz Y, Mechine-Neuville A, Stoll I, Bellocq J, Rio M, et al. Presence of high levels of MT1-MMP protein in fibroblastic cells of human invasive carcinomas. Int J Cancer. 1999;82(2):208\u201312.","journal-title":"Int J Cancer"},{"key":"7150_CR58","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2005;1755(1):37\u201369.","DOI":"10.1016\/j.bbcan.2005.03.001"},{"issue":"9","key":"7150_CR59","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1158\/0008-5472.CAN-05-4012","volume":"66","author":"UW Nilsson","year":"2006","unstructured":"Nilsson UW, Dabrosin C. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res. 2006;66(9):4789\u201394.","journal-title":"Cancer Res"},{"issue":"9","key":"7150_CR60","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1158\/0008-5472.CAN-08-0295","volume":"68","author":"C Bendrik","year":"2008","unstructured":"Bendrik C, Robertson J, Gauldie J, Dabrosin C. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res. 2008;68(9):3405\u201312.","journal-title":"Cancer Res"},{"issue":"1","key":"7150_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.canlet.2009.11.002","volume":"292","author":"C Bendrik","year":"2010","unstructured":"Bendrik C, Karlsson L, Dabrosin C. Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer. Cancer Lett. 2010;292(1):32\u201340.","journal-title":"Cancer Lett"},{"issue":"8","key":"7150_CR62","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.4049\/jimmunol.1202610","volume":"190","author":"KS Leifler","year":"2013","unstructured":"Leifler KS, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J, et al. Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol. 2013;190(8):4420\u201330.","journal-title":"J Immunol"},{"issue":"5","key":"7150_CR63","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti\u2013VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391\u2013400.","journal-title":"Nat Rev Drug Discov"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07150-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T15:07:18Z","timestamp":1650208038000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07150-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7150"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07150-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Research Ethics Committee of State University of Campinas - UNICAMP (CAAE: 83156117.8.0000.5404), and the written informed consent was signed for all applicable patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"660"}}